DOCSLIB.ORG

Compliments of Pharmavoice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compliments of Pharmavoice ARTIFICIAL INTELLIGENCE SHOWCASE Driving Drug Innovation With AI The global AI market has been showing rapid growth as major pharmaceutical and medical technology companies invest heavily in internal and external AI partnerships. ccording to some reports, more than key objective is to predict which patients are 50% of executives expect broad scale at risk of cardiovascular disease and then de- How Pharma Can Use A AI adoption by 2025. Further, reve- termine the treatments that might work best. nue generated through AI-based solutions in Scientists at Janssen Research & Devel- AI for Drug Innovation the industry is projected to rise at a CAGR opment have found a way to use AI to speed Create internal expertise and of 21.94% and reach $2.199 billion by 2022, the process of discovering new potential treat- according to Frost & Sullivan. Meanwhile a ments. They are using AI to sort through support AI employees with the right report by Global Market Insights forecasts how cells representing certain diseases react resources that the U.S. healthcare AI market will exceed to a variety of compounds. Then, through Collaborate with start-ups and $10 billion by 2024. With total investment collaborations with academic partners, they others using AI in drug discovery exceeding $7.2 billion across 300-plus deals are using computer algorithms to predict how Partner with academic groups that between 2013 and 2018, the pharmaceutical other cells are likely to react to those same focus on AI R&D industry continues to lead the healthcare sector compounds. The benefit for scientists is they in terms of attracting AI-related VC funding. don’t have to start over for every study, which Consider open science projects or The COVID-19 pandemic has propelled means they can potentially get treatments to various R&D challenges growth in AI investments with a new wave of patients faster. Source: A Guide to AI in the Pharmaceutical Industry, transformative technologies being developed Many other companies are partnering with Stefani Group in an effort to contain the pandemic, such as AI leaders to drive innovation. For example, smart machines and robots. AI is also being Pfizer formed a partnership with Atomwise put to use to determine the effectiveness of to help identify potential new drug targets by nology to find treatments that will mitigate existing drugs in the treatment of the virus. using deep neural networks toPharmaVOICE quickly analyze disease complications that arise during and millions of molecules. This further expands after infection. Its Project Prodigy platform Pfizer’s AI-led initiatives, which have included maps all known drugs against every possible Transformation Through AI partnerships with IBM Watson and invest- mechanism in which the COVID-19 virus ment in MIT’s Machineof Learning for Pharma- operates and causes complications, and seeks to Many pharmaceutical companies see huge ceutical Discovery and Synthesis Consortium. build scenarios to identify non-obvious medi- opportunities to transform their operations Other pharmaceutical companies have cal solutions as well as non-linear risks. with AI capabilities, from productivity im- formed partnerships with Atomwise to drive provements to better outcomes across the drug discovery, including Merck, Bayer, and value chain to using AI to create new offerings. AbbVie. In addition, AbbVie is working with Challenges to AI Innovation AI is top of mind for GSK, which an- AiCure to monitor medication adherence in nounced plans to recruit 80 AI specialists by patients with schizophrenia. One of the biggest barriers to growth in the end of 2020. The company’s AI head- One small biotech company that has been AI capabilities is the limited number of AI ex- quarters will be in San Francisco, but experts putting AI into practice in its drug develop- perts. According to a report by Tencent, there will be spread across Europe and the United ment process is Verge Genomics. The com- are about 300,000 AI researchers and practi- States. The goal is to use AI in the search for pany uses similar processes to those that power tioners worldwide but the market demand is treatments in various therapeutic categories, Google’s search engines to map out hundreds for millions of roles. Other barriers include including cancer and autoimmune diseases. of genes that cause disease, and from there regulatory pathways. Since innovation must The company is also working with several AI find drugs that target all the genes at once. By be balanced with safety risks, there is a need platform developers to advance drug discovery. using AI, Verge is taking products into clini- for robust strategies to enable well-considered Another company that is investing heavily cal trials rapidly thanks to its approach. For ex- market surveillance for AI-led innovations. in AI is Bayer. Together with Merck, Bayer ample, it is expected to start a small molecule AI is only as good as the innovators behind has developed the CTEPH Pattern Recogni- ALS program in 2021, followed by four more it, with experts noting that to deliver results, tion AI Software to help radiologists recognize programs. It has achieved this by building a users must ask the right questions and work chronic thromboembolic pulmonary hyper- massive database of brain tissue sequences. with clean data. In Verge’s case, the com- tension, a rare form of hypertension. FDA has Another biotech company committed to pany started its work in human rather than granted breakthroughCompliments designation for the soft- AI is Healx, which has created an AI platform animal models, combining its brain sequence ware, which will be deployed through Bayer’s for rare diseases. The company’s purpose built database with human genetics, overlaid with Radimetrics platform. AI platform, Healnet, serves to fill crucial gaps human-derived neurons. This let researchers In addition, Bayer is using a combination in knowledge about rare diseases and speed the identify gene signatures that appear in pa- of real-world data and AI-driven solutions to discovery of new treatments. tients. improve the characterization and stratification Another AI-driven bioscience company, Despite the challenges, the importance of (c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact [email protected] of disease as well as patient populations. A Biovista, is applying augmented and AI tech- AI in drug development is now well-under- 24 October 2020 ● PharmaVOICE SHOWCASE ARTIFICIAL INTELLIGENCE EXECUTIVE VIEWPOINTS Rich Christie, M.D., Mike Weber On-Demand Reproducibility Ph.D. VP of Product Pharma companies work in a highly Chief Development Management regulated environment, and in addition Officer Aktana to using AI to drive data insights it AiCure is vital to ensure compliance with regulations, especially computer systems validation requirements. For this purpose AI Provides Patient Support It’s All About Balance traceability and reproducibility of data AI-powered solutions are playing a Implementing AI effectively is all about is key. Hence, being able to capture and pivotal role to keep patients engaged balance. The key is finding an AI partner reproduce on demand a trail of how in their trials, ensure visibility into their who excels at integrating all data an AI system predicted an outcome is well-being, and maintain communication assets, coordinating all stakeholders key. This places an additional onus on by providing multiple avenues of and leveraging existing technical and implementation and effective use of AI support. Sponsors of clinical trials and analytics investments. A well-rounded systems. sites need data mining and advanced AI implementation that can be deployed analytic capabilities to safeguard trials quickly, adopted effortlessly and can Jerome Premmereur, with meaningful insights and limited data generate practical suggestions and insights M.D. variability, especially when supporting for users allows the organization to focus VP, Patient Safety trials remotely. on agility, continuous improvement and Solutions and extracting the most value from their AI. Adjudication Michelle Marlborough PharmaVOICECovance Chief Product Officer Agility and Vigilance AiCure Production-grade AI models take work Time, Resources, and Quality to maintain. As markets shift, models AI is helping a lot in the equation of drift, especially in theof face of unexpected three variables that safety is dealing change, like COVID-19. Pharma companies with, wondering how we can get must establish a diligent practice of balance. The three variables are time, Enhancing the Patient Experience ingesting recent data, retraining AI models, resources, and quality. One cannot be Partnering with AI vendors that have and regularly evaluating their predictive perfect without sacrificing the other solutions that truly reach patients where health to ensure they haven’t degraded. two. Time is regulated and cannot be they are, and that use technology already Companies must also remember that as AI adjusted above the traditional reports at a patient’s disposal to enhance patient changes, so do the workflows of its users. of 7/15 days for expedited safety reports engagement will empower study teams This agility requires eternal vigilance, but (ESR). Resources are very substantial at sponsors, sites, and CROs to focus the competitive advantages that result can if the quality of the report is at the on the patient experience. Furthermore, be remarkable. level expected and on time. AI is fast. A this focus on partnering with technology learning machine on natural language vendors will also give study teams the Dinesh Kasthuril processing (NLP) can read hundreds of patient data visibility needed via a single Global Head, Client pages much faster than any physician dashboard to help them make data- Relationships and Project and can extract the elements that are driven decisions that can greatly impact Management important in a narrative for the ESR. the successful administration of an Covance Patient Safety Therefore, time, resources, and quality ongoing study.Compliments are able to achieve a new and better s stood.
Load more

Recommended publications
  • Honoring Catalysts in Action Over the Winter and Spring Through Our Website, Facebook and Twitter
    8 CONNEC TCFS We have been honored to share the stories of 25 Catalysts Honoring Catalysts in Action over the winter and spring through our website, Facebook and Twitter. We hope you’ll take time to read about their remarkable lives and the courage and persistence they Throughout this issue of SolveCFS we pay tribute to the collective action demonstrate every day. As unique as each one is, they are united in their hope that research led by the CFIDS that has led up to the launch of the Association’s latest research initiative: Association of America will lead to better treatment and the research institute without walls (RIWW). Two individuals warrant spe - healthier futures. cial attention for their immensely important contributions. First, James York , the first person consented and enrolled to participate in the SolveCFS BioBank. James was working as an underwater camera man and marine coordinator in the film industry when pneumonia turned into CFS in 2004. He has turned to writing when cognitive impairment can be kept at bay, as a form of expression and, occasionally, compensation. James enrolled in the BioBank as soon as it was announced. He returned his signed consent James York, adrift and at work on the form promptly; completed the extensive medical award-winning film “Ocean Men: Extreme history questionnaire thoroughly and expeditiously Dive” with an IMAX Mark II camera and even recruited his own matched control to partici - housing in Stargate Cave on Andros Island pate. He gave blood samples and tissue swabs. He did in the Bahamas. The picture explored the so as part of an odyssey to learn about CFS and cope beauty and science of breath-hold diving with it.
    [Show full text]
  • AMERICAN HELLENIC CHAMBER of COMMERCE Amcham.Gr
    2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com 2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ DIRECTORY 2019 AMERICANHELLENIC CHAMBER OF COMMERCE amcham.gr KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. 2 | DIRECTORY 2019 KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. contents U.S. PAGES 105 The United States Government in Greece ..... 106 The Commercial Service U.S. Embassy Athens...................... 108 U.S. Government Agencies and Offices ...... 110 Business and Professional Organizations in the United States ....................... 112 American Chambers of Commerce CHAMBER PAGES 17 in Europe ...............................
    [Show full text]
  • Molecular Medicine Tri-Conference
    Register by January 15 and SAVE up to $200 Premier Sponsors Corporate Sponsors Conference: February 3-5 | Exhibits: February 3-4 Moscone North Convention Center | San Francisco, CA PLENARY KEYNOTES When Drug Research is Personal John F. Crowley, Founder, Novazyme Pharmaceuti cals, Inc. Technology, Aging, and the Brain Biotechnologies GmbH ® Gary W. Small, M.D., Professor, Meso Scale Discovery David Geff en School of Medicine, University of California, Los Angeles Chips, Clones and Living Beyond 100 Paul J.H. Schoemaker, Ph.D., Lead Sponsoring Publicati ons M.B.A., Professor, Wharton School of Business Corporate Support Sponsors Co - Sponsors The State of California Cambridge Healthtech Institute • 250 First Avenue, Suite 300, Needham, MA 02494 Telephone: 781-972-5400 or Toll-Free in the U.S. 888-999-6288 • Fax: 781-972-5425 Tri-Conference.com Media Partners CONFERENCE-AT-A-GLANCE Tuesday, February 2 The Open Access Publisher 8:00 AM Morning Short Course Registration and Coffee 9:00 - 12:00 PM Morning Short Courses (Courses 1-6) 10:15 - 10:30 Networking Coffee Break 1:00 - 2:00 Afternoon Short Course Registration 2:00 - 5:00 Afternoon Short Courses (Courses 7-12) 3:15 - 3:30 Networking Refreshment Break 5:00 Close of Day Wednesday, February 3 7:00 AM Registration and Morning Coffee 8:00 - 9:40 Plenary Keynotes 9:40 - 11:00 Grand Opening Refreshment Break in the Exhibit Hall Nanomedicine 11:00 - 12:40 PM Concurrent Channels 12:40 - 1:45 Sponsored Luncheon Presentations or Lunch on Your Own 1:45 - 2:15 Dessert in the Exhibit Hall 2:15 - 4:20
    [Show full text]
  • The Intellectual Property, Licensing, and Business Development Event of the Year
    CLP & CPEEarn Credit CLE, OCTOBER 14 –17 Sheraton Centre Toronto Toronto, ON, Canada The Intellectual Property, Licensing, and Business Development Event of the Year FEATURING THESE CUTTING-EDGE TOPICS: Connecting & Collaborating: The Convergence of Life Sciences and High Tech Carving Out Your Commercial Space — Strategies and Trade Offs Is High Tech Crazy? Are We Experiencing a Patent Bubble? Benches Unleashed: Judicial Views on Fixing the Systems The Role of IP in Rebuilding Economies Following the Arab Spring How Outcomes of Patent Fights have Changed the Course of History REGISTER BY JULY 31 & SAVE $200! www.LE S2012.org WHO SHOULD ATTEND: Don’t Miss Your Opportunity Professionals to Connect and Collaborate involved with: Business Join more than 1,000 of your colleagues for the LES 2012 Annual Meeting, Development October 14 –17 in Toronto. Intellectual Property The LES Annual Meeting is the must-attend IP, licensing, and business development event Investments of the year — featuring 3½ days of high-quality educational sessions, ample networking Legal opportunities and the industry’s leading Tech Fair. Licensing Open Innovation Fuel Your Network Technology Transfer The LES Annual Meeting provides ample opportunities to connect with your colleagues. R&D Various events, including receptions, breakfasts, lunches and breaks, will allow you to discuss your day-to-day challenges and unique issues with other licensing professionals from around the world. You’re sure to learn tips, tactics and strategies that you can apply From the following back at your workplace. industries: Biotechnology Chemicals & Discover New Resources and Solutions Materials The LES Annual Meeting Tech Fair on October 16 is a vital extension of the educational program and represents a valuable opportunity to cultivate resources that will help you Consumer Products and your organization stay ahead of the competition.
    [Show full text]
  • Drug Repositioning: Extracting Added Value from Prior R&D Investments
    Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. InsightPharmaReports.com Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. Published in July 2010 by Cambridge Healthtech Institute • www.InsightPharmaReports.com • Reproduction prohibited i Insight Pharma Reports is a division of Cambridge Healthtech Institute, a world leader in life science information and analysis through conferences, research reports, and targeted publications. Insight Pharma Reports focus on pharmaceutical R&D—the technologies, the companies, the markets, and the strategic business impacts. They regularly feature interviews with key opinion leaders; surveys of the activities, views, and plans of individuals in industry and nonprofit research; and substantive assessments of technologies and markets. Managers at the top 50 pharma companies, the top 100 biopharma companies, and the top 50 vendors of tools and services rely on Insight Pharma Reports as a trusted source of balanced and timely information. Related Report Data Mining in Drug Development and Translational Medicine by Hermann A.M. Mucke, Ph.D. General Manager: Alfred R. Doig, Jr. 781-972-1348, [email protected] Editorial Operations Director: Laurie Sullivan 781-972-1353, [email protected] Design Director: Tom Norton 781-972-5440, [email protected] Production Director: Ann Handy 781-972-5493, [email protected] Marketing Manager: James Prudhomme 781-972-5486, [email protected] Customer Service: Rose LaRaia 781-972-5444, [email protected] Corporate Subscriptions: David Cunningham 781-972-5472, [email protected] Global Report Sales: Jack Valeri 781-972-1355, [email protected] Insight Pharma Reports, 250 First Ave., Suite 300, Needham, MA 02494 www.InsightPharmaReports.com ii • www.InsightPharmaReports.com • Reproduction prohibited Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M.
    [Show full text]
  • Digital R&D: the Next Frontier for Biopharmaceuticals
    Digital R&D │ The Next Frontier for Biopharmaceuticals The Next Frontier Digital R&D The Next Frontier for Biopharmaceuticals Pharmaceuticals and Medical Products Practice 2017 Designed by the US Design Center Copyright © McKinsey & Company, Inc. www.mckinsey.com Digital R&D The Next Frontier for Biopharmaceuticals 2017 Editors Sastry Chilukuri Ann Westra For more info please contact [email protected] Contents 1 Digital in R&D—the $100 billion opportunity Sastry Chilukuri, Edd Fleming, and Ann Westra R&D in the age of analytics 13 Real-world evidence: From activity to impact Olivia Cavlan, Sastry Chilukuri, Matthias Evers, and Ann Westra 31 Randomized pragmatic trials: Can they fulfill their promise? Arnaub Chatterjee, Sastry Chilukuri, Michael Pencina, Eric Peterson, Saif Rathore, and Vijay Vaidya 35 The next generation in clinical operations performance Sastry Chilukuri, Edd Fleming, Eoin Leydon, Fareed Melhem, and Michael Steinmann 47 Moving beyond serendipity in drug discovery Sastry Chilukuri, Leeland Ekstrom, Jonathan Usuka, and Ann Westra 61 Digital vigilance: Building the backbone for insight-driven safety Kate Chavez and Brandon Parry 69 How big data can revolutionize pharmaceutical R&D Jamie Cattell, Sastry Chilukuri, and Michael Levy Connecting with the individual customer 85 Medical affairs: Key imperatives for engaging and educating physicians in a digital world Matthias Evers, Ivan Ostojic, Brindan Suresh, Josh Weiner, and Ann Westra 101 Engaging patients during clinical trials Montana Cherney, Amit Paley, Leslie Ruckman,
    [Show full text]
  • Top 100 AI Leaders in Drug Discovery and Advanced Healthcare Introduction
    Top 100 AI Leaders in Drug Discovery and Advanced Healthcare www.dka.global Introduction Over the last several years, the pharmaceutical and healthcare organizations have developed a strong interest toward applying artificial intelligence (AI) in various areas, ranging from medical image analysis and elaboration of electronic health records (EHRs) to more basic research like building disease ontologies, preclinical drug discovery, and clinical trials. The demand for the ML/AI technologies, as well as for ML/AI talent, is growing in pharmaceutical and healthcare industries and driving the formation of a new interdisciplinary industry (‘data-driven healthcare’). Consequently, there is a growing number of AI-driven startups and emerging companies offering technology solutions for drug discovery and healthcare. Another important source of advanced expertise in AI for drug discovery and healthcare comes from top technology corporations (Google, Microsoft, Tencent, etc), which are increasingly focusing on applying their technological resources for tackling health-related challenges, or providing technology platforms on rent bases for conducting research analytics by life science professionals. Some of the leading pharmaceutical giants, like GSK, AstraZeneca, Pfizer and Novartis, are already making steps towards aligning their internal research workflows and development strategies to start embracing AI-driven digital transformation at scale. However, the pharmaceutical industry at large is still lagging behind in adopting AI, compared to more traditional consumer industries -- finance, retail etc. The above three main forces are driving the growth in the AI implementation in pharmaceutical and advanced healthcare research, but the overall success depends strongly on the availability of highly skilled interdisciplinary leaders, able to innovate, organize and guide in this direction.
    [Show full text]
  • MMM2013 Finalists.Indd
    GlimpseGlimpse Aatat panel of 100 esteemed industryGoldGold leaders and thinkers spent several hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the results of their e orts—the 2013 fi nalists ollowing two exhaustive rounds of scoring by 100 or so inde- Make no mistake. Judging the MM&M Awards is a serious business. pendent industry judges, the results are in for the MM&M If you need further proof, take a look at some of the photographs FAwards 2013. The nalists for each category are revealed on from the judging day (pages 62-66), each conveying the dedication the following pages—but you’ll have to wait for the spectacular and hard work that goes into the review process. dinner and ceremony on October 2, 2013 to nd out who will take It’s not enough for a submission simply to look good, either—it home the gold and silver awards. must also be effective. That’s why, as well as assembling a band of The MM&M Awards are judged with the utmost independence seasoned creatives, we recruited more than 30 marketing and brand- and authority, using ing execs from the pharma industry to further extend the authority an esteemed panel of and credibility of the judging process. (See opposite for a complete leaders and thinkers list of 2013 judges.) MMM representing a wide We would like to take this opportunity to thank all of our judges variety of disciplines and for their efforts. backgrounds within the As usual, the identities of all gold and silver winners will be withheld 2013 healthcare marketing until the spectacular gala dinner at Cipriani 42nd Street on October community.
    [Show full text]
  • Past Attendees Have Represented
    Past attendees have represented: 20/20 GeneSystems 23andMe 5AM Solutions, Inc. Abundance Partners Accelerated Cure Project for Multiple Sclerosis Actus Biotechnologies Addario Lung Cancer Medical Institute Addi and Cassi Fund Adenoid Cystic Carcinoma Research Foundation Ader Investment Management Aeras Global TB Vaccine Foundation aha Group Alberta Cancer Foundation Alexandria University Alliance for Lupus Research Alpha-1 Foundation ALS Therapy Development Institute Alzheimer's Association Alzheimer's Drug Discovery Foundation Amarantus Biosciences, Inc. American Academy of Dermatology Association American Enterprise Institute American Heart Association Apollo Management Apple Tree Partners Ares Management, LLC Arizona State University Arthritis Foundation Asmacure Ltee Aspen Brain Forum Assay Depot Assn of American Publishers/Prof & Scholarly ATP Private Equity Partners Aurec Group Austen BioInnovation Institute Autism Speaks Battelle Bay Area Lyme Fund Bay Area Physical Sciences Oncology Center BayBio BCC Partners Beach Point Capital Beats of Laughter Becton Dickinson Beyond Batten Disease Foundation Beyond The Ask Inc. Biobasix Inc. BioCentury Publications BioCycive BioMotiv BioRings LLC BioStrategies Inc. Biotechnology Industry Organization Biovista, Inc. BLL Partners, LLC Bloomberg/Newsroom Blueprint Medicines Boehringer Ingelheim Pharmaceuticals, Inc. Bonnie J Addario Lung Cancer Foundation Boston Children's Hospital Boston University Brain & Behavior Research Foundation Brain Canada Break Through Cancer Coalition Breakout Labs
    [Show full text]
  • REGISTRO INTEGRATORI Giugno 2009
    REGISTRO INTEGRATORI PER PRODOTTO - aggiornato a giugno 2009 PRODOTTO DITTA CODICE + 37° ERBORISTERIA DOTT. CECCHINI E 06 22130-Y 05 BOMBER CLOROFILLA X AD 09803-Y 1 AL GIORNO INDEL X AD 01032-Y 1 P ERBA VITA E 08 35501-Y 100% CREAPURE DEGUSSA ASOLI FARMACEUTICI X AD 07383-Y 100% CREATINA MONOIDRATA VITAMIN SHOP X AD 09262-Y 100% CREATINA MONOIDRATA BODY EVOLUTION I 07 04501-Y 100% CREATINA PURE FITNESS PRODUCTS X AD 09472-Y 100% DESTOCK LABORATOIRES FORTE' PHARMA M 07 31649-Y 100% EGG PRO EXTRA vg EUROSUP X AD 03547-Y 100% ISO WHEY NEWTRITIONS N 09 40118-Y 100% L-GLUTAMINE FISIOPLUS N 08 31834-Y 100% MALTODEX ULTIMATE ITALIA X AD 03157-Y 100% PREMIUM MELATONIN INTERPHARM HERBES I 07 30545-Y 100% PREMIUM SAW PALMETTO INTERPHARM HERBES E 07 30546-Y 100% PURE PLATINUM WHEY NEWTRITIONS N 09 38800-Y 100% SIERO ISOLATE DIETA & FITNESS N 07 32885-Y 100% WHEY ULTIMATE ITALIA I 06 19388-Y 100% WHEY DELITE AMEFIT I 06 15475-Y 100% WHEY GOLD STANDARD NUTRIZEN N 08 35736-Y 100% WHEY GOLD STANDARD VARI GUSTI NUTRICA N 08 35430-Y 100% WHEY PROTEIN SPORT E FITNESS N 09 38814-Y 100% WHEY PROTEIN JUST NATURAL X AD 08705-Y 100% WHEY PROTEIN BOOSTER I 06 18526-Y 100% WHEY PROTEIN FUEL ABS I 06 19973-Y 100% WHEY PROTEIN FUEL FAST ENERGY I 06 15830-Y 19 ERBE PHARMA GREEN E 08 33210-Y 19 ERBE ZERMAT LIMITED E 06 19083-Y 2 GLUT AKG MOLDES N 09 41262-Y 20 ERBE LARIX LABORATORI E 09 40372-Y 24 HR PROTEIN SOLUTION FAST ENERGY I 06 18409-Y 3 CARBONE FINOCCHIO PAPAIA FA RO M 07 33944-Y 3 CREA COMPRESE PHARMATEAM N 09 42682-Y 3 P 1 OTI X AD 00315-Y 3 P 2 OTI X AD
    [Show full text]
  • Solving the Problem of New Uses by Creating Incentives for Private Industry to Repurpose Off-Patent Drugs
    SOLVING THE PROBLEM OF NEW USES DRAFT 9/15/14 SOLVING THE PROBLEM OF NEW USES BY CREATING INCENTIVES FOR PRIVATE INDUSTRY TO REPURPOSE OFF-PATENT DRUGS Benjamin N. Roin* Sept. 15, 2014 Abstract One of the most dramatic public-policy failures affecting biomedical research is the lack of incentives for industry to develop new therapeutic uses (“indications”) for off-patent drugs—generally known as “the problem of new uses.” Recent technological advances have allowed researchers to identify hundreds of potential new indications for older drugs that could address critical unmet medical needs. And researchers are poised to discover hundreds more. Developing new uses for FDA-approved drugs (known as “drug repurposing”) is much faster, cheaper, and less risky than developing new drugs, and therefore offers what may be the single most promising avenue for delivering new medical treatments to the public. Many commentators argue that a viable business model to support drug repurposing could solve the pharmaceutical industry’s protracted “productivity crisis,” and that it would provide the NIH with a pathway across the proverbial “Valley of Death” in biomedical research. Unfortunately, that business model does not exist. Pharmaceutical companies invariably lose interest in developing new uses for drugs once generics enter the market. The prior scholarship on this problem attributes it to a gap in the patent-based incentives for drug development. But the government already offers patent rights for new uses of existing drugs, which could provide the appropriate incentives for developing those new medical treatments. On paper, these new-use patents give pharmaceutical companies the right to charge payers when physicians prescribe an off-patent drug for a new use without preventing patients from using low-cost generics for the drug’s older, unpatented uses.
    [Show full text]
  • Redirect Repurposing of Drugs: Innovative Revision of Cancer Treatment
    KU Leuven Biomedical Sciences Group Faculty of Pharmaceutical Sciences Department of Pharmaceutical and Pharmacological Sciences ReDIReCT Repurposing of Drugs: Innovative Revision of Cancer Treatment Ciska Verbaanderd Ciska VERBAANDERD Ciska VERBAANDERD Jury: SupervisorCiska VERBAANDERDProf. Isabelle Huys Co-Supervisors Prof. Ilse Rooman Dr. Greet Musch Chair Prof. Pieter Annaert Dissertation presented in Jury membersCiska VERBAANDERD Prof. Eric Van Cutsem partial fulfilment of the Prof. Jeroen Luyten requirements for the Dr. Denis Lacombe degree of Doctor in Dr. Daniel O’Connor Pharmaceutical Sciences Ciska VERBAANDERD Dissertation presented in Ciska VERBAANDERD partial fulfilment of the Jury: September 2020 Supervisor Prof. Isabelle Huys requirements for the degree of Doctor in Co-Supervisors Prof. Ilse Rooman Dr. Greet Musch Pharmaceutical Sciences Ciska VERBAANDERD Chair Prof. Pieter AnnaertSeptember 2020 Jury members Prof. Jeroen Luyten Prof. Eric Van Cutsem Dissertation presented in Prof. x partial fulfilment of the Ciska VERBAANDERDProf. x September 2020 requirements for the degree of Doctor in Aan mijn liefste papa Van wie we afscheid hebben moeten nemen tijdens dit onderzoeksproject DANKWOORD Een doctoraat wordt vaak (terecht) beschreven als een traject met veel hoogtepunten maar ook uitdagingen en beproevingen. Gelukkig heb ik dit traject niet alleen moeten afleggen en werd ik omringd door een heleboel gemotiveerde mensen. Ik zou daarom graag iedereen willen bedanken die mij de voorbije vier jaar gesteund en geholpen heeft. Ten eerste zou ik graag mijn promotor en copromotoren willen bedanken voor hun enorme steun en bijdrage aan dit project. Isabelle, bedankt voor het vertrouwen en voor alle kansen die je mij gegeven hebt. Jij hebt mij onvoorwaardelijk gesteund de afgelopen vier jaar, niet alleen op professioneel maar ook op persoonlijk vlak.
    [Show full text]